Treatment results for pediatric cancer and blood diseases
At New Children’s Hospital, we treat cancer, blood disorder, and stem cell transplant patients. We are the only hospital in Finland that provides pediatric CART cell therapy and allogeneic stem cell transplants. Our treatment outcomes are at a high level by international comparison.
We administer intravenous chemotherapy to cancer patients and treat patients with benign blood diseases. On a nationwide level, we provide photopheresis therapy for patients with severe graft versus host rejection, as well as erythrocyte apheresis therapy for patients with severe hemoglobinopathy.
We have experts in all clinical and diagnostic fields at our disposal.
In 2021, our inpatient ward had approximately 5,500 treatment days, 1,200 day hospital visits, approximately 930 procedures requiring anesthesia, and approximately 5,500 outpatient visits. We also welcome foreign patients.
International cooperation
We work in close collaboration with international partners. We participate in international collaboration on, e.g., NOPHO (Nordisk Förening för Pediatrisk Hematologi och Onkologi), EBMT (The European Society for Blood and Marrow Transplantation) and PedNet (Pediatric Net work on haemophilia management) for Finland. JACIE (Joint Accreditation Committee of ISCT/ EBMT) accredited our stem cell transplantation activities as the first pediatric center in the Nordic countries and Finland in 2008. New Children’s Hospital has a tissue establishment license granted by FIMEA.
We are a member in the European Reference Network for pediatric oncology (ERN-PedCan) and rare blood diseases (ERN-EuroBloodNet) programs. We are a member of the network on early phase trials of cancel therapies for children and adolescents (ITCC Innovative Therapies for Children with Cancer).
